Literature DB >> 11398181

Chemokine antagonist infusion promotes axonal sparing after spinal cord contusion injury in rat.

R S Ghirnikar1, Y L Lee, L F Eng.   

Abstract

Spinal cord injury produced by mechanical contusion causes the onset of acute and chronic degradative events. These include blood brain barrier disruption, edema, demyelination, axonal damage and neuronal cell death. Posttraumatic inflammation after spinal cord injury has been implicated in the secondary injury that ultimately leads to neurologic dysfunction. Studies after spinal cord contusion have shown expression of several chemokines early after injury and suggested a role for them in the ordered recruitment of inflammatory cells at the lesion site (McTigue et al. [1998] J. Neurosci. Res. 53:368-376; Lee et al., [2000] Neurochem Int). We have demonstrated previously that infusion of the broad-spectrum chemokine receptor antagonist (vMIPII) in the contused spinal cord initially attenuates leukocyte infiltration, suppresses' gliotic reaction and reduces neuronal damage after injury. These changes are accompanied by increased expression of bcl-2, the endogenous apoptosis inhibitor, and reduced neuronal apoptosis (Ghirnikar et al. [2000] J. Neurosci. Res. 59:63-73). We demonstrate that 2 and 4 weeks of vMIPII infusion in the contusion-injured spinal cord also results in decreased hematogenous infiltration and is accompanied by reduced axonal degeneration in the gray matter. Luxol fast blue and MBP immunoreactivity indicated reduced myelin breakdown in the dorsal and ventral funiculi. Increased neuronal survival in the ventral horns of vMIPII infused cords was seen along with increased bcl-2 staining in them. Immunohistochemical identification of fiber phenotypes showed increased presence of calcitonin gene related peptide, choline acetyl transferase and tyrosine hydroxylase positive fibers as well as increased GAP43 staining in treated cords. These results suggest that sustained reduction in posttraumatic cellular infiltration is beneficial for tissue survival. A preliminary report of this study has been published (Eng et al. [2000] J. Neurochem. 74(Suppl):S67B). In contrast to vMIPII, infusion of MCP-1 (9-76), a N-terminal analog of the MCP-1 chemokine showed only a modest reduction in cellular infiltration at 14 and 21 dpi without significant tissue survival after spinal cord contusion injury. Comparing data on tissue survival obtained with vMIPII and MCP-1 (9-76) further validate the importance of the use of broad-spectrum antagonists in the treatment of spinal cord injury. Controlling the inflammatory reaction and providing a growth permissive environment would enhance regeneration and ultimately lead to neurological recovery after spinal cord injury. J. Neurosci. Res. 64:582-589, 2001. Published 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11398181     DOI: 10.1002/jnr.1110

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  16 in total

1.  Temporal mRNA profiles of inflammatory mediators in the murine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine model of Parkinson's disease.

Authors:  R Pattarini; R J Smeyne; J I Morgan
Journal:  Neuroscience       Date:  2007-01-29       Impact factor: 3.590

2.  Characterization of the interactions of vMIP-II, and a dimeric variant of vMIP-II, with glycosaminoglycans.

Authors:  Bo Zhao; Patricia J Liwang
Journal:  Biochemistry       Date:  2010-08-24       Impact factor: 3.162

3.  Transgenic inhibition of astroglial NF-kappa B improves functional outcome in experimental autoimmune encephalomyelitis by suppressing chronic central nervous system inflammation.

Authors:  Roberta Brambilla; Trikaldarshi Persaud; Xianchen Hu; Shaffiat Karmally; Valery I Shestopalov; Galina Dvoriantchikova; Dmitry Ivanov; Lubov Nathanson; Scott R Barnum; John R Bethea
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

Review 4.  Monocyte chemoattractant protein-1 (MCP-1): an overview.

Authors:  Satish L Deshmane; Sergey Kremlev; Shohreh Amini; Bassel E Sawaya
Journal:  J Interferon Cytokine Res       Date:  2009-06       Impact factor: 2.607

5.  Inflammation and Spinal Cord Injury: Infiltrating Leukocytes as Determinants of Injury and Repair Processes.

Authors:  Alpa Trivedi; Andrea D Olivas; Linda J Noble-Haeusslein
Journal:  Clin Neurosci Res       Date:  2006-12

Review 6.  Response of chemokine antagonists to inflammation in injured spinal cord.

Authors:  Lawrence F Eng; Yuen Ling Lee
Journal:  Neurochem Res       Date:  2003-01       Impact factor: 4.414

7.  Syndromics: a bioinformatics approach for neurotrauma research.

Authors:  Adam R Ferguson; Ellen D Stück; Jessica L Nielson
Journal:  Transl Stroke Res       Date:  2011-11-18       Impact factor: 6.829

Review 8.  Chemokine-ligands/receptors: multiplayers in traumatic spinal cord injury.

Authors:  Friederike Knerlich-Lukoschus; Janka Held-Feindt
Journal:  Mediators Inflamm       Date:  2015-04-21       Impact factor: 4.711

9.  Central nervous system injury triggers hepatic CC and CXC chemokine expression that is associated with leukocyte mobilization and recruitment to both the central nervous system and the liver.

Authors:  Sandra J Campbell; V Hugh Perry; Fernando J Pitossi; Angus G Butchart; Mariela Chertoff; Sara Waters; Robert Dempster; Daniel C Anthony
Journal:  Am J Pathol       Date:  2005-05       Impact factor: 4.307

10.  The privileged immunity of immune privileged organs: the case of the eye.

Authors:  Inbal Benhar; Anat London; Michal Schwartz
Journal:  Front Immunol       Date:  2012-09-21       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.